Arvind Reddy Devanabanda
Cardiovascular Disease · Peoria, ILNPI 1578974069
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.3%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Abbott at 45.9% of the total. Reporting peaked in 2021 at $9,245 and has fallen 67.4% since, to $3,014 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $81.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$16K
- Medtronic$6K
- Edwards Lifesciences$6K
- W. L. Gore & Associates, Inc.$2K
- Boston Scientific$1K
- Penumbra, Inc.$1K
- plus $2K from 17 others
What the payments were for
- Consulting fees$4301%
- Grants$6,00018%
- Travel & lodging$11,01832%
- Food & beverage$16,41348%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 77 | $15,599 |
| Medtronic(2 entities) | 74 | $6,218 |
| Edwards Lifesciences | 171 | $5,941 |
| W. L. Gore & Associates, Inc. | 15 | $1,865 |
| Boston Scientific | 30 | $1,448 |
| Penumbra, Inc. | 4 | $1,312 |
| Novartis | 13 | $367 |
| Inari Medical, Inc. | 3 | $286 |
| Amgen | 4 | $186 |
| Teleflex LLC | 2 | $162 |
| Bard Peripheral Vascular, Inc. | 1 | $100 |
| ZOLL Circulation Inc | 2 | $100 |
| Lemaitre Vascular, Inc. | 3 | $65 |
| Livanova USA, Inc. | 2 | $53 |
| Cardiovascular Systems Inc. | 2 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $50 |
| Heartflow, Inc. | 1 | $46 |
| Pfizer | 2 | $45 |
| Angiodynamics, Inc. | 1 | $20 |
| Abiomed | 1 | $20 |
| Bayer | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Cordis US CORP. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip System$4,500
- OPTIS$4,179
- PERCLOSE PROGLIDE$1,536
- Dragonfly OCT$1,500
- VenaSeal$1,377
- TurboHawk$1,321
- XACT$1,319
- Indigo System$1,312
- GORE CARDIOFORM Septal Occluder$944
- COREVALVE EVOLUT R$830
- Edwards SAPIEN 3 Transcatheter Heart Valve$814
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$509
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$389
- FLOWTRIEVER CATHETER, S$388
- WATCHMAN Access System$369
- Abre$300
- Resolute$244
- Diamondback Peripheral$216
- CT THROMBECTOMY SYSTEM KIT$149
- DRAGONFLY OPSTAR$149
How this compares
$33,976 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 293 | $297,704 |
| JardianceEmpagliflozin | 65 | $58,939 |
| BrilintaTicagrelor | 56 | $52,018 |
| EntrestoSacubitril/Valsartan | 45 | $49,971 |
| XareltoRivaroxaban | 31 | $40,969 |
| Repatha SyringeEvolocumab | 13 | $7,618 |
| ClopidogrelClopidogrel Bisulfate | 431 | $4,812 |
| Metoprolol Succinate | 445 | $4,456 |
| Atorvastatin Calcium | 344 | $2,375 |
| Ranolazine ErRanolazine | 26 | $1,361 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 76 | $1,228 |
| Furosemide | 252 | $1,166 |
| Amiodarone Hcl | 48 | $1,162 |
| Amlodipine Besylate | 127 | $846 |
| Losartan Potassium | 111 | $768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $297,704293 claims |
| NovartisEntresto | $367 | $49,97145 claims |
| Johnson & JohnsonXarelto | $14 | $40,96931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Peoria
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Robert KochLibertyville$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.